Ibrance + Faslodex as 1st Tx Improves Outcomes for HR+ HER2- MBC

Options
Moderators
Moderators Member Posts: 25,912
edited October 2020 in Stage IV/Metastatic Breast Cancer, Open to All To Contribute

Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer
October 27, 2020
Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone. Read more...

· Share on FacebookShare on Twitter

Categories